Diatech gets peptide labeling patent

Article

Peptide imaging agent developer Diatech of Londonderry, NH, hasreceived a broad patent from the U.S. Patent and Trademark Officecovering its core technology of attaching peptides to technetium-99mradioisotopes. The patent covers Diatech's work on several

Peptide imaging agent developer Diatech of Londonderry, NH, hasreceived a broad patent from the U.S. Patent and Trademark Officecovering its core technology of attaching peptides to technetium-99mradioisotopes. The patent covers Diatech's work on several products,including agents for imaging disease states such as deep veinthrombosis, pulmonary emboli, tumors and atherosclerotic plaque.Diatech said the patent puts it in a strong proprietary positionas it works to commercialize the agents.

The company also announced this month that it has receiveda $100,000 grant from the Heart and Lung Blood Institute divisionof the National Institutes of Health to research a potential newtherapeutic agent for the treatment of blood clots.

Recent Videos
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
Related Content
© 2025 MJH Life Sciences

All rights reserved.